公开(公告)号：US20200262919A1

公开(公告)日：2020-08-20

申请号：US16648568

申请日：2018-10-12

Applicant: MERCK SHARP & DOHME CORP. ,  AMGEN INC.

Inventor： Zachary ZIMMERMAN ,  Xiaohong Alicia ZHANG ,  Peter Christopher HOLLAND ,  Janet FRANKLIN ,  Gregory FRIBERG

IPC: C07K16/28 ,  A61P35/00

Abstract: Methods and compositions for treating diffuse large B cell lymphoma (DLBCL) using a combination of blinatumomab and/or a blinatumomab variant and pembrolizumab, a pembrolizumab variant and/or an antigen-binding fragment thereof, are provided.

公开(公告)号：US20240261289A1

公开(公告)日：2024-08-08

申请号：US18562107

申请日：2022-05-17

Applicant: AMGEN INC.

Inventor： Haby HENARY ,  Gataree NGARMCHAMNANRITH ,  Joseph PARK ,  Sandeep DUTTA ,  Gregory FRIBERG ,  Brett E. HOUK ,  Omar MATHER

IPC: A61K31/519 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K45/06 ,  A61P35/00

Abstract: Provided herein are methods of treating a cancer comprising a KRAS G12C mutation in a patient with active brain metastases, comprising administering sotorasib to the patient in amount effective to treat the cancer.

公开(公告)号：US20190040141A1

公开(公告)日：2019-02-07

申请号：US15955304

申请日：2018-04-17

Applicant: Amgen Inc.

Inventor： Pedro J. BELTRAN ,  Frank J. CALZONE ,  Gregory FRIBERG ,  Christopher HAQQ ,  Anthony W. TOLCHER

IPC: C07K16/28

Abstract: The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

公开(公告)号：US20220323446A1

公开(公告)日：2022-10-13

申请号：US17696758

申请日：2022-03-16

Applicant: Amgen Inc.

Inventor： Gregory FRIBERG ,  Haby HENARY ,  Brett E. HOUK ,  Omar A. MATHER ,  Gataree NGARMCHAMNANRITH ,  Sandeep DUTTA

IPC: A61K31/519 ,  A61K31/573 ,  A61K33/00 ,  A61K33/10 ,  A61K33/08 ,  A61K31/4439 ,  A61K31/426 ,  A61K31/341 ,  A61K31/4164 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/675 ,  A61K31/513 ,  A61K31/4166 ,  A61K31/496 ,  A61K31/435 ,  A61K31/495 ,  A61K31/536 ,  A61K31/517 ,  A61K31/439 ,  A61K31/7048 ,  A61K31/445 ,  A61K31/506 ,  A61K31/4985 ,  A61K31/58 ,  A61K31/40 ,  A61K31/522 ,  A61K31/5513 ,  A61K31/167 ,  A61K31/635 ,  A61K31/337 ,  A61P35/00 ,  A61K9/00

Abstract: Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

公开(公告)号：US20150079022A1

公开(公告)日：2015-03-19

申请号：US14549050

申请日：2014-11-20

Applicant: AMGEN INC.

Inventor： Gregory FRIBERG ,  Marc PAYTON

IPC: A61K31/506 ,  A61K38/19

CPC classification number: A61K31/506 ,  A61K38/193 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.

Abstract translation: 本发明涉及使用AMG 900，一种小分子泛极光激酶抑制剂，用于治疗癌症，包括实体瘤，血液衍生的肿瘤等。 本发明还提供了用于施用AMG 900以治疗癌症的药物组合物，剂量范围和治疗方案。

公开(公告)号：US20250127782A1

公开(公告)日：2025-04-24

申请号：US18689716

申请日：2022-09-07

Applicant: AMGEN INC.

Inventor： Emily CHAN ,  Gregory FRIBERG ,  Omar Ali MATHER ,  Brett E. HOUK ,  Gataree NGARMCHAMNANRITH ,  Haby HENARY ,  Sandeep DUTTA

IPC: A61K31/519 ,  A61K31/4745 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising administering to the patient sotorasib and an anti-epidermal growth factor receptor (EGFR) antibody in amounts effective to treat the cancer. Further provided herein are methods further comprising administering FOLFIRI (irinotecan, 5-FU and leucovorin) to the patient.

公开(公告)号：US20130323198A1

公开(公告)日：2013-12-05

申请号：US13906231

申请日：2013-05-30

Applicant: AMGEN INC.

Inventor： Gregory FRIBERG ,  Marc PAYTON

IPC: A61K31/506 ,  A61K38/19

CPC classification number: A61K31/506 ,  A61K38/193 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.

Abstract translation: 本发明涉及使用AMG 900，一种小分子泛极光激酶抑制剂，用于治疗癌症，包括实体瘤，血液衍生的肿瘤等。 本发明还提供了用于施用AMG 900以治疗癌症的药物组合物，剂量范围和治疗方案。